Serum IL-10 levels have been found to positively correlate with tumor progression; moreover, studies have revealed that IL-10+ TAMs act as a signaling molecule that promotes immune evasion in breast, gastric, and bladder cancers, negatively correlating with overall patient survival and recurrence-free survival [90–92]. Here, IL10 is linked to neoplasm.